What is William Blair's Estimate for Genmab A/S Q4 Earnings?

Key Points

• William Blair has raised its Q4 2025 earnings estimate for Genmab A/S to $0.44 per share, up from $0.42, while the consensus full-year earnings estimate is $1.45 per share.
• In its last quarterly report, Genmab A/S reported earnings of $0.54 per share, exceeding expectations, and its revenue was $925 million, which was below analysts' expectations of $5.77 billion.
• Analysts are divided on Genmab's stock rating, with two issuing a Strong Buy, six a Buy, and one a Sell, leading to a consensus rating of Moderate Buy with a target price of $40.80.

Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) - Equities researchers at William Blair increased their Q4 2025 earnings estimates for shares of Genmab A/S in a report issued on Monday, October 20th. William Blair analyst M. Phipps now anticipates that the company will post earnings of $0.44 per share for the quarter, up from their previous forecast of $0.42. The consensus estimate for Genmab A/S's current full-year earnings is $1.45 per share.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.15. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%.The business had revenue of $925.00 million during the quarter, compared to analysts' expectations of $5.77 billion. Genmab A/S has set its FY 2025 guidance at EPS.

Other analysts have also issued research reports about the company. Guggenheim upgraded Genmab A/S from a "neutral" rating to a "buy" rating and set a $43.00 price target on the stock in a report on Tuesday, September 23rd. Wall Street Zen downgraded shares of Genmab A/S from a "strong-buy" rating to a "buy" rating in a research note on Saturday. HC Wainwright reissued a "buy" rating and issued a $40.00 price objective on shares of Genmab A/S in a research note on Wednesday, October 15th. Truist Financial increased their target price on Genmab A/S from $45.00 to $46.00 and gave the stock a "buy" rating in a research note on Tuesday, July 8th. Finally, Weiss Ratings reissued a "hold (c)" rating on shares of Genmab A/S in a research note on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $40.80.

Genmab A/S Price Performance

Shares of GMAB stock opened at $30.54 on Tuesday. The company has a market cap of $19.61 billion, a PE ratio of 15.35, a price-to-earnings-growth ratio of 1.85 and a beta of 0.98. Genmab A/S has a 1 year low of $17.24 and a 1 year high of $33.65. The stock's 50 day simple moving average is $28.14 and its two-hundred day simple moving average is $23.47.

Institutional Investors Weigh In On Genmab A/S

Several large investors have recently modified their holdings of the business. Allspring Global Investments Holdings LLC bought a new position in shares of Genmab A/S during the third quarter valued at approximately $210,000. Merit Financial Group LLC bought a new stake in Genmab A/S during the 3rd quarter valued at $200,000. Ethic Inc. purchased a new position in shares of Genmab A/S in the 3rd quarter valued at $476,000. Blue Trust Inc. raised its holdings in Genmab A/S by 24.4% in the third quarter. Blue Trust Inc. now owns 12,283 shares of the company's stock worth $377,000 after purchasing an additional 2,412 shares in the last quarter. Finally, CWM LLC boosted its stake in Genmab A/S by 28.3% in the third quarter. CWM LLC now owns 2,306 shares of the company's stock valued at $71,000 after acquiring an additional 509 shares in the last quarter. Institutional investors own 7.07% of the company's stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.